Preliminary Evaluation of Next-Generation Sequencing Performance Relative to qPCR and In Vitro Cell Culture Tests for Human Cytomegalovirus

References

1. 1.↵
   1. Knipe D. M,
   2. Howley P. M.

   1. Mocarski E. S. Jr..,
   2. Shenk T.,
   3. Pass R. F.

   Cytomegaloviruses. In Fields Virology, 5th ed.; Knipe D. M, Howley P. M. , Eds.; Lippincott Williams & Wilkins: Philadelphia, 2007; pp 2701–2772.
2. 2.↵
   1. Dolan A.,
   2. Cunningham C.,
   3. Hector R. D.,
   4. Hassan-Walker A. F.,
   5. Lee L.,
   6. Addison C.,
   7. Dargan D. J.,
   8. McGeoch D. J.,
   9. Gatherer D.,
   10. Emery V. C.,
   11. Griffiths P. D.,
   12. Sinzger C.,
   13. McSharry B. P.,
   14. Wilkinson G. W.,
   15. Davison A. J.

   Genetic content of wild-type human cytomegalovirus. J. Virol. 2004, 85 (Pt 5), 1301–1312.

   OpenUrl
3. 3.↵
   1. Gatherer D.,
   2. Seirafian S.,
   3. Cunningham C.,
   4. Holton M.,
   5. Dargan D. J.,
   6. Baluchova K.,
   7. Hector R. D.,
   8. Galbraith J.,
   9. Herzyk P.,
   10. Wilkinson G. W.,
   11. Davison A. J.

   High-resolution human cytomegalovirus transcriptome. Proc. Natl. Acad. Sci. USA 2011, 108 (49), 19755–19760.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Staras S. A.,
   2. Dollard S. C.,
   3. Radford K. W.,
   4. Flanders W. D.,
   5. Pass R. F.,
   6. Cannon M. J.

   Seroprevalence of cytomegalovirus infection in the United States, 1988–1994. Clin. Infect. Dis. 2006, 43 (9), 1143–1151.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Dasari V.,
   2. Smith C.,
   3. Khanna R.

   Recent advances in designing an effective vaccine to prevent cytomegalovirus-associated clinical diseases. Expert. Rev. Vaccines 2013, 12 (6), 661–76.

   OpenUrlPubMed
6. 6.↵
   Food and Drug Administration. Guidance for Industry: Characterization and qualification of cell substrates and other biological materials used in the production of viral vaccines for infectious disease indications. U.S. Department of Health and Human Services, 2010.
7. 7.↵
   WHO Expert Committee on Biological Standardization. Annex 3: Recommendations for the evaluation of animal cell cultures as substrates for the manufacture of biological medicinal products and for the characterization of cell bank. WHO Technical Report Series, No 978: World Health Organization, 2013.
8. 8.↵
   European Directorate for the Quality of Medicines & HealthCare. 2.6.16: Tests for extraneous agents in viral vaccines for human use. European Pharmacopoeia 8.0: Council of Europe, 2013.
9. 9.↵
   1. Plotkin S. A.,
   2. Furukawa T.,
   3. Zygraich N.,
   4. Huygelen C

   Candidate cytomegalovirus strain for human vaccination. Infect. Immun. 1975, 12 (3), 521–517.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    European Directorate for the Quality of Medicines & HealthCare. 2.6.21: Nucleic acid amplification techniques. European Pharmacopoeia 8.0; Council of Europe, 2013.
11. 11.↵
    1. Bird B. H.,
    2. Bawiec D. A.,
    3. Ksiazek T. G.,
    4. Shoemaker T. R.,
    5. Nichol S. T.

    Highly sensitive and broadly reactive quantitative reverse transcription-PCR assay for high-throughput detection of Rift Valley fever virus. J. Clin. Microbiol. 2007, 45 (11), 3506–3513.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Pripuzova N.,
    2. Wang R.,
    3. Tsai S.,
    4. Li B.,
    5. Hung G. C.,
    6. Ptak R. G.,
    7. Lo S. C.

    Development of real-time PCR array for simultaneous detection of eight human blood-borne viral pathogens. PLOS One 2012, 7 (8), e43246.

    OpenUrlPubMed
13. 13.↵
    1. Watzinger F.,
    2. Suda M.,
    3. Preuner S.,
    4. Baumgartinger R.,
    5. Ebner K.,
    6. Baskova L.,
    7. Niesters H. G.,
    8. Lawitschka A.,
    9. Lion T.

    Real-time quantitative PCR assays for detection and monitoring of pathogenic human viruses in immunosuppressed pediatric patients. J. Clin. Microbiol. 2004, 42 (11), 5189–5198.

    OpenUrlAbstract/FREE Full Text